PeterMD Review: The $149 GLP-1 That Charges $464.84 On Day One

For compounded semaglutide: $464.84, charged once, for a supply PeterMD estimates at 10 to 12 weeks. That is the $447 card price plus a $17.84 service fee added at checkout. Spread across the generous end of PeterMD's own estimate — twelve weeks, three four-week cycles — it is $154.95 a cycle and about $2,014 a year; at the ten-week end it is $185.94 a cycle and $2,417. For compounded tirzepatide: $672.82, charged once, for what the page calls quarterly billing, which is $224.27 a month and $2,691 a year. Both figures were read on August 9, 2026 by putting the products in a real cart and opening the checkout, not off the marketing page.

Because PeterMD divided the block by a number of months the block does not contain. The card states three things at once: "$149/Month", "$447 Total", and "Estimated 10–12 week supply". $447 divided by $149 is exactly three, so the monthly figure assumes thirteen weeks of medicine from a pack PeterMD itself caps at twelve. The Level 2 card is worse: "$139/Month · $834 Total · Estimated 8-12 week supply" divides by six. And on the twin page at /startsemaglutide/ the label is written out in full — "$149.00, Monthly cost on a 10-12 week supply" — which is not a monthly price but a block price with a division printed next to it.

It is 3.99% of your subtotal, and PeterMD does not explain it. It appears for the first time in the order summary — $17.84 on the $447 GLP-1 block, $25.82 on the $647 tirzepatide block, $33.28 on the $834 Level 2 block — sitting under a header banner that promises "Simple, upfront pricing" and above a shipping line that is genuinely free. The string "Service Fee" does not occur on any product page, on the homepage, in the Terms and Conditions, or in the Refund and Auto-Bill Policy. It is small in absolute terms and it is the whole gap between PeterMD's advertised price and its real one, so budget 4% on top of whatever number brought you to the checkout.

Not from the tirzepatide page. That page repeats "Get Started for $149. Then $249 per month • billed quarterly" three times, and every one of those CTAs resolves to the same link, which adds "Tirzepatide – 60mg" at $647.00 to the cart. The checkout then shows $672.82 and offers a credit card and nothing else — no instalments, no financing, no first-payment option. PeterMD's own catalogue prices "Tirzepatide – 3 Month" at the same $647.00, which is what identifies the 60mg vial as the quarter. So $149 is not the first payment on a plan; on that page it is not a payment at all.

Yes, and it takes some work to establish that from the page you are most likely to land on. /glp1-b12, the page the main menu links to, calls the product "GLP1" from top to bottom and never names the molecule in its own copy — the word semaglutide appears only inside a patient testimonial and in the filename of the product photograph, Semaglutide-Solo-transparent.png. PeterMD publishes the identical page a second time at /startsemaglutide/ with "semaglutide" substituted everywhere "GLP1" appears, which settles it first-party. It is compounded rather than branded: PeterMD's own weight-loss page says "Our GLP1 uses the same active ingredient, compounded by trusted pharmacies" as Ozempic and Wegovy.

No, and this matters more than the wording suggests. The GLP-1 page says the program "delivers FDA-approved medication to your door"; the tirzepatide page lists "FDA-approved and clinically proven" as a product bullet; the weight-loss hub's FAQ says of GLP1, "It's FDA-approved and highly effective." What PeterMD sells is compounded — its own copy says so two paragraphs away — and compounded drugs are not FDA-approved, do not undergo pre-market review, and are not what the cited trials studied. Describing them that way is the specific claim FDA has been writing to telehealth sellers about through 2025 and 2026. PeterMD has not received such a letter; the language on its pages is nevertheless the language those letters are about.

Almost certainly not. PeterMD's Refund and Auto-Bill Policy reads: "All purchases of Peter M.D treatments are final once medication is received. Due to stringent pharmacy regulations governing prescription medications, we are unable to accept returns or provide refunds, regardless of whether the product remains unused." Damaged or defective goods are replaced rather than refunded, and only if you email a photograph within 24 hours of delivery. Auto-renewals must be cancelled by email at least 48 hours before the renewal date, and the policy states plainly that it will be produced to the merchant processor in a chargeback dispute. Since everything is billed as one up-front block, that means the smallest amount you can be wrong about is $464.84.

Probably. The checkout's own state selector — the WooCommerce configuration rather than a sentence on a page — offers 48 states plus the District of Columbia, and the two it leaves out are Alabama and Idaho, exactly matching the "Not available in these states: AL, ID" printed on the product pages. If you want the semaglutide + B12 program specifically, two more come off: that page's notice reads "Not available in these states: AL, ID, AK, HI". Tirzepatide is available in Alaska and Hawaii; the GLP-1 block is not.

Because PeterMD has never taken its old pages down. The nav-linked pages price the GLP-1 block at $447 and $834 and tirzepatide at $647. The orphaned page at /glp1-weight-loss/ still advertises "Semaglutide Injections $105 per month" and "$134 per month", and the product catalogue still carries live, purchasable GLP-1 and tirzepatide SKUs at $250, $270 and $299, some on pages that list a completely different set of excluded states. None of those is reachable from the menu, so none is what a new patient is routed to — but all of them are live URLs a search engine can send you to. If you arrive on a PeterMD page quoting a price lower than the ones here, check the checkout total before you believe it.

No. The live FDA warning-letter index was queried on August 9, 2026 for "petermd" and "getpetermd" — zero records each — and for "peter md" and "peter m.d", which return eighteen letters apiece, all of which were read. They are vape, tobacco and medical-device letters, plus a June 2025 clinical-investigator letter addressed to a physician named Peter Michael, M.D., who is a different person at a different address and is not this company; it is not filed here, because a name resemblance is not a match. Both pharmacies PeterMD names in its Terms were screened as well and neither has a letter. A control query for a company known to hold a 2026 telehealth letter returned it under the same query shape.